TY  - GEN
AU  - Ledermann,Jonathan A
AU  - Oza,Amit M
AU  - Lorusso,Domenica
AU  - Aghajanian,Carol
AU  - Oaknin,Ana
AU  - Dean,Andrew
AU  - Colombo,Nicoletta
AU  - Weberpals,Johanne I
AU  - Clamp,Andrew R
AU  - Scambia,Giovanni
AU  - Leary,Alexandra
AU  - Holloway,Robert W
AU  - Gancedo,Margarita Amenedo
AU  - Fong,Peter C
AU  - Goh,Jeffrey C
AU  - O'Malley,David M
AU  - Armstrong,Deborah K
AU  - Banerjee,Susana
AU  - García-Donas,Jesus
AU  - Swisher,Elizabeth M
AU  - Cameron,Terri
AU  - Maloney,Lara
AU  - Goble,Sandra
AU  - Coleman,Robert L
TI  - Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial
SN  - 1474-5488
PY  - 2020///0709
KW  - Aged
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - administration & dosage
KW  - Carcinoma
KW  - drug therapy
KW  - Disease Progression
KW  - Double-Blind Method
KW  - Female
KW  - Humans
KW  - Indoles
KW  - Middle Aged
KW  - Neoplasm Recurrence, Local
KW  - Ovarian Neoplasms
KW  - Platinum
KW  - Poly(ADP-ribose) Polymerase Inhibitors
KW  - Progression-Free Survival
KW  - Treatment Outcome
N1  - Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1016/S1470-2045(20)30061-9
ER  -